Mechanism of action
Memantine is a voltage-dependent, noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors in the central nervous system. NMDA receptors are glutamate-gated ion channels that play a critical role in synaptic plasticity, learning, and memory.
In Alzheimer disease, chronic low-level activation of NMDA receptors by excessive glutamate leads to sustained calcium influx, mitochondrial dysfunction, and neuronal death—a process known as excitotoxicity. Memantine blocks the NMDA receptor channel in a use-dependent manner when it is excessively activated, but allows physiologic activation during normal synaptic transmission. This selective blockade is achieved because memantine has moderate affinity and rapid on-off kinetics, so it occupies the channel only when glutamate levels are pathologically elevated.
By reducing excitotoxic damage, memantine may slow cognitive and functional decline. Unlike cholinesterase inhibitors (donepezil, rivastigmine, galantamine), which enhance cholinergic transmission, memantine modulates glutamatergic pathways and represents a complementary mechanism of action.
- Memantine is a noncompetitive NMDA receptor antagonist used for moderate-to-severe Alzheimer disease.
- It blocks excessive NMDA receptor activation, reducing glutamate excitotoxicity and neuronal calcium overload.
- Unlike cholinesterase inhibitors, memantine modulates glutamatergic (not cholinergic) transmission.
- Can be combined with donepezil or other cholinesterase inhibitors for additive benefit.
- Common side effects: dizziness, confusion, headache; does NOT cause the GI upset seen with cholinesterase inhibitors.
- Primarily renally excreted unchanged; dose reduction required in moderate-to-severe renal impairment.
- Urinary alkalinizers (sodium bicarbonate, carbonic anhydrase inhibitors) decrease renal clearance and increase memantine levels.
- Long half-life (60–80 hours) allows once-daily dosing and gradual titration.
Indications
Memantine is FDA-approved for:
- Moderate-to-severe Alzheimer disease: The primary indication. Often added when cholinesterase inhibitors alone are insufficient or when disease has progressed beyond the mild stage.
Memantine is commonly used in combination with a cholinesterase inhibitor (e.g., donepezil) because the two classes have complementary mechanisms and may provide additive symptomatic benefit.
Off-label uses
- Vascular dementia (limited evidence)
- Mild cognitive impairment (not established)
- Neuropathic pain syndromes (investigational)
Memantine does not reverse or cure Alzheimer disease; it may modestly slow progression of symptoms and delay functional decline.
Pharmacokinetics
- Absorption: Well absorbed orally; bioavailability ~100%. Food does not significantly affect absorption.
- Distribution: Widely distributed; volume of distribution 9–11 L/kg. Crosses the blood-brain barrier.
- Metabolism: Minimal hepatic metabolism. Undergoes partial hydroxylation and glucuronidation, but most of the drug is excreted unchanged.
- Elimination: Primarily renal (57–82% unchanged in urine). Half-life is long: 60–80 hours, allowing once-daily dosing. Renal impairment significantly prolongs half-life.
- Renal dosing: Dose reduction required in moderate-to-severe renal impairment (CrCl <30 mL/min).
The long half-life means steady state is reached in about 2 weeks. Dosing follows the product label with gradual titration to minimize adverse effects.
Adverse effects
Memantine is generally well tolerated, especially compared to cholinesterase inhibitors. Common and serious adverse effects include:
Common
- Dizziness (5–7%)
- Headache (5–6%)
- Confusion (5–6%)
- Constipation (3–5%)
- Somnolence
Neuropsychiatric
- Hallucinations (rare, but more common in patients with Lewy body dementia or Parkinson disease dementia)
- Agitation, anxiety
Cardiovascular
- Hypertension (occasionally)
- Rare reports of syncope
Other
- Fatigue
- Back pain
- Urinary incontinence (or retention in some cases)
Black box warning: None.
Memantine does not typically cause the gastrointestinal side effects (nausea, vomiting, diarrhea) that are common with cholinesterase inhibitors, making it better tolerated in some patients.
Contraindications and warnings
Contraindications
- Known hypersensitivity to memantine or any component of the formulation.
Warnings and precautions
- Severe renal impairment: Dose reduction required; avoid in end-stage renal disease unless benefits outweigh risks. Urinary alkalinization (e.g., vegetarian diet, sodium bicarbonate, carbonic anhydrase inhibitors) reduces renal clearance and increases drug levels.
- Seizure disorders: Use with caution; memantine may lower seizure threshold in susceptible patients.
- Genitourinary conditions: May worsen urinary retention or bladder outflow obstruction (much less than anticholinergics, but caution still advised).
- Cardiovascular disease: Use with caution in patients with heart failure or recent myocardial infarction.
- Neuropsychiatric symptoms: May exacerbate hallucinations or confusion, particularly in dementia with Lewy bodies or Parkinson disease dementia. Monitor closely.
Pregnancy and lactation
- Pregnancy category: Not assigned under current FDA labeling (older category B). Limited human data; use only if clearly needed.
- Lactation: Unknown if excreted in breast milk; caution advised, though rarely relevant given patient population.
Memantine is not a controlled substance.
Drug interactions
Memantine has relatively few clinically significant drug interactions.
Pharmacodynamic interactions
- Other NMDA antagonists (ketamine, dextromethorphan, amantadine): Theoretical additive effects; use together with caution.
- Anticholinergic agents: No direct interaction, but both may worsen confusion. Memantine is often given with cholinesterase inhibitors (which have opposite, pro-cholinergic effects).
- CNS depressants: Additive sedation possible.
Pharmacokinetic interactions
- Urinary alkalinizers (sodium bicarbonate, carbonic anhydrase inhibitors, vegetarian diets): Decrease renal clearance of memantine by reducing tubular secretion of the ionized form. Can increase memantine levels by 80% or more; monitor for toxicity.
- Drugs that alter urinary pH: Acidifying agents (ammonium chloride, high-dose vitamin C) increase renal clearance and may reduce efficacy.
- Cimetidine, ranitidine, hydrochlorothiazide, triamterene: Share renal cationic transport pathway; potential for reduced clearance, but clinically modest.
No significant CYP450 interactions; memantine does not induce or inhibit major hepatic enzymes.
Clinical pearls
- Memantine vs. cholinesterase inhibitors: Memantine targets glutamate/NMDA pathways; cholinesterase inhibitors boost acetylcholine. They can be used together for additive benefit in moderate-to-severe Alzheimer disease.
- Typical exam scenario: A patient with moderate Alzheimer disease on donepezil continues to decline; adding memantine is the next step.
- Titration: Dosing follows the product label with gradual titration to minimize dizziness and confusion.
- Monitoring: No routine lab monitoring required. Assess renal function at baseline if moderate-to-severe impairment suspected.
- Urinary pH matters: Vegetarian diets, antacids, and urinary alkalinizers can double memantine levels. Counsel patients and check medication list.
- Not for mild Alzheimer disease: FDA approval is for moderate-to-severe disease. Cholinesterase inhibitors are preferred in mild disease.
- Does not cause GI upset: Unlike cholinesterase inhibitors (which commonly cause nausea, vomiting, diarrhea), memantine is GI-sparing.
- Long half-life: Takes ~2 weeks to reach steady state; effects are not immediate. Similarly, discontinuation effects may persist.
- Not habit-forming: No abuse potential; not a controlled substance.
- Lewy body dementia caution: Memantine may worsen hallucinations in dementia with Lewy bodies or Parkinson disease dementia; use with careful monitoring or avoid.
NMDA (memantine's target) = Neurons May Die from Activation (excitotoxicity blocked by memantine)
Practice questions
1. A 72-year-old man with moderate Alzheimer disease has been taking donepezil 10 mg daily for 18 months. Despite good adherence, his Mini-Mental State Examination score has declined from 18 to 14, and his daughter reports worsening memory and increased difficulty with activities of daily living. Physical examination shows no focal neurological deficits. Which of the following is the most appropriate next step in management?
2. A 68-year-old woman with moderate Alzheimer disease is started on memantine. She has a history of chronic kidney disease with a creatinine clearance of 25 mL/min. Two weeks after starting standard-dose memantine therapy, she develops worsening confusion, dizziness, and agitation. Which of the following factors most likely contributed to her symptoms?
3. A 75-year-old man with moderate Alzheimer disease is being treated with memantine and donepezil. His daughter mentions that he recently started taking sodium bicarbonate tablets for heartburn. Over the next month, he develops increased confusion and visual hallucinations. Laboratory studies show normal renal function. Which of the following best explains his symptoms?
Frequently asked questions
How does memantine work?
Memantine works by blocking NMDA receptors in the brain in a voltage-dependent, noncompetitive manner. It prevents excessive glutamate activity and reduces calcium-mediated excitotoxicity, which contributes to neuronal damage in Alzheimer disease. Unlike cholinesterase inhibitors, it modulates glutamatergic rather than cholinergic transmission, offering a complementary mechanism for symptom management.
What are the side effects of memantine?
Common side effects include dizziness, headache, confusion, and constipation. Memantine is generally well tolerated and notably does not cause the gastrointestinal upset (nausea, vomiting, diarrhea) typical of cholinesterase inhibitors. Rare neuropsychiatric effects like hallucinations can occur, particularly in patients with Lewy body dementia. Severe adverse effects are uncommon.
Is memantine a controlled substance?
No, memantine is not a controlled substance. It has no abuse potential or risk of dependence. It is a prescription medication approved by the FDA for moderate-to-severe Alzheimer disease, but it does not produce euphoria, sedation, or other effects that would classify it as a controlled drug.
Memantine vs donepezil — what is the difference?
Memantine is an NMDA receptor antagonist that blocks glutamate excitotoxicity, while donepezil is a cholinesterase inhibitor that increases acetylcholine levels. Memantine is approved for moderate-to-severe Alzheimer disease; donepezil is used across all stages. They have different mechanisms and side-effect profiles, and are often combined for additive benefit. Memantine causes less GI upset than donepezil.
Can memantine be used with other dementia medications?
Yes, memantine is commonly combined with cholinesterase inhibitors like donepezil, rivastigmine, or galantamine for moderate-to-severe Alzheimer disease. The combination provides complementary mechanisms—memantine modulates glutamate, while cholinesterase inhibitors enhance acetylcholine. Combination therapy may offer modest additive cognitive and functional benefits. Monitor for increased confusion or other adverse effects when combining.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06DX01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.